Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108064 | 0.84 | KMT2A (0.57) | KMT2ATDP1MAPTKDM3BPPARG | |
| SCHEMBL12478127 | 0.84 | KMT2A (1.00) | KMT2ATDP1KDM3BTSHRSMN1; SMN2 | |
| SCHEMBL104485 | 0.83 | KMT2A (0.51) | KMT2ATDP1MAPTSMN1; SMN2GAA | |
| SCHEMBL1227831 | 0.80 | KMT2A (0.62) | KMT2ATDP1MAPTKDM3BRXFP1 | |
| SCHEMBL18640323 | 0.78 | KMT2A (0.60) | KMT2ATDP1MAPTKDM3BRXFP1 | |
| SCHEMBL29007135 | 0.76 | KMT2A (0.54) | KMT2ATDP1MAPTKDM3BRXFP1 | |
| SCHEMBL101704 | 0.75 | KMT2A (0.50) | KMT2ATDP1MAPTKDM3BPPARG | |
| SCHEMBL21345745 | 0.73 | KMT2A (0.54) | KMT2ATDP1MAPTKDM3BRXFP1 | |
| SCHEMBL17376302 | 0.72 | KDM4E (0.54) | KMT2ATDP1MAPTPPARGNCOA2 | |
| SCHEMBL2384930 | 0.72 | KMT2A (0.50) | KMT2ATDP1MAPTKDM3BRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1745 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| CN-106170553-A | Modified nucleic acid molecules and uses thereof | 现代治疗公司 | 2016-11-30 | — | — | CN | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2016043661-A1 | MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-03-24 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-0311694-A1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RIKAGAKU KENKYUSHO (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0147689-A2 | A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | KMT2A 973/4885TDP1 132/4885MAPT 3517/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | KMT2A 1435/4885TDP1 176/4885MAPT 3589/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | KMT2A 1435/4885TDP1 176/4885MAPT 3589/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | KMT2A 973/4885TDP1 132/4885MAPT 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.